1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,432 | 0,462 | 22.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cereno Scientific to evaluate CS1 with advanced imaging technology | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| Do | Cereno Scientific submitted Type C meeting request with FDA for Phase II drug candidate CS1 in preparation for further clinical development | 1 | Cision News | ||
| Mi | Cereno Scientific received approval to initiate sub-study of the CS1 EAP using Fluidda's innovative imaging technology to obtain insights on the long-term disease-modifying potential of CS1 in PAH | 2 | Cision News | ||
| 14.02. | Cereno Scientific to attend BIO-Europe Spring 2025 - a leading partnering event for life science in Europe | 3 | Cision News | ||
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 145 | Edison Investment Research | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | |
| 11.02. | Cereno Scientific's HDAC inhibitor CS014 advances | 1 | Cision News | ||
| 11.02. | Cereno Scientific's HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study | 1 | Cision News | ||
| 06.02. | Cereno Scientific to present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US | 1 | Cision News | ||
| 27.12.24 | Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH | 2 | Cision News | ||
| 20.12.24 | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated | 1 | Cision News | ||
| 16.12.24 | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 13.12.24 | Cereno Scientific to present and engage in partnering and investor meetings at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco | 3 | Cision News | ||
| 06.12.24 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 29.11.24 | Cereno Scientific reports insider share purchases | 1 | Cision News | ||
| 28.11.24 | Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen | 3 | Cision News | ||
| 28.11.24 | Cereno Scientific - A productive period with plenty more to come | 247 | Edison Investment Research | Cereno Scientific has released its Q324 results, marking a productive and strategically significant period. Following the positive top-line data from the Phase IIa safety study of CS1 in pulmonary arterial... ► Artikel lesen | |
| 26.11.24 | Cereno Scientific releases BioStock article highlighting Q3 Report 2024 | 2 | Cision News | ||
| 26.11.24 | CERENO SCIENTIFIC: Impactful third quarter for Cereno | 1 | Cision News | ||
| 21.11.24 | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the AHA Scientific Sessions 2024 | 2 | Cision News | ||
| 21.11.24 | Cereno Scientific AB: Cereno Scientific publishes the interim report for Q3 2024 (July 1-September 30) | 126 | GlobeNewswire (Europe) | The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2024 (July 1-September 30).
Summary of the interim report for Q3 2024 (July 1-September 30)
Cereno... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,375 | -0,33 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| TEMPUS AI | 68,13 | -11,20 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,560 | -0,95 % | Harmony Biosciences price target cut to $42 at Mizuho | ||
| ARVINAS | 17,770 | -3,27 % | Arvinas Inc.: Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,010 | 0,00 % | Dyne Therapeutics SVP Richard Scalzo verkauft Aktien im Wert von 34.707 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 9,265 | -10,48 % | Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) | ||
| SPRINGWORKS THERAPEUTICS | 58,24 | -2,77 % | Merck KGaA: Wechsel im Top-Management - wann schlägt der DAX-Konzern bei SpringWorks zu? | Die Aktie von Merck KGaA notiert weiterhin in der Nähe des 52-Wochen-Tiefs. Das bestätigte Übernahmeinteresse an SprinWorks Therapeutics hat den DAX-Wert jüngst unter Druck gesetzt, denn die Marktteilnehmer... ► Artikel lesen | |
| EVOTEC | 8,520 | -0,35 % | Evotec Aktie: Ein erneuter Dämpfer! | Der Hamburger Wirkstoffforscher Evotec verzeichnet am Montag weitere Kursverluste an der Börse. Im XETRA-Handel fiel die Aktie am Vormittag um mehr als zwei Prozent auf 8,53 Euro. Bereits zum Handelsstart... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,810 | -1,58 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and... ► Artikel lesen | |
| BIONTECH | 114,20 | +0,44 % | Vervielfachungspotenzial mit KI-Newcomer NetraMark! Palantir und BioNTech in einer Aktie! | "Gamechanger"! "Quantensprung"! "Revolution"! Für die Möglichkeiten von Künstlicher Intelligenz (KI) in der Medizin verwenden Experten zahlreiche Superlative. Fest steht, dass KI riesiges Potenzial... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,430 | +1,76 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| DISC MEDICINE | 54,53 | +0,33 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| ABSCI | 4,960 | -4,43 % | Absci Corporation: Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery | VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,440 | -8,15 % | Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies | ||
| SUMMIT THERAPEUTICS | 22,090 | -4,21 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,005 (-1,23 %) liegt der Kurs bei 0,433 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.
